Clover Health Investments, Corp. Share Price

Equities

CLOV

US18914F1030

Managed Healthcare

Market Closed - Nasdaq 01:30:00 25/05/2024 am IST 5-day change 1st Jan Change
1 USD +1.09% Intraday chart for Clover Health Investments, Corp. +12.36% +5.03%
Sales 2024 * 133.85Cr 11TCr Sales 2025 * 134.85Cr 11TCr Capitalization 50Cr 4.12TCr
Net income 2024 * -11Cr -888.54Cr Net income 2025 * -9.5Cr -788.89Cr EV / Sales 2024 * 0.31 x
Net cash position 2024 * 8.25Cr 685.09Cr Net cash position 2025 * 7.17Cr 595.4Cr EV / Sales 2025 * 0.31 x
P/E ratio 2024 *
-4.99 x
P/E ratio 2025 *
-5.52 x
Employees 552
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.15%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Clover Health Investments, Corp., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (CLOV) CLOVER HEALTH INVESTMENTS Posts Q1 Revenue $346.9M, vs. Street Est of $321.2M MT
Clover Health Investments, Corp. announces an Equity Buyback for $20 million worth of its shares. CI
Clover Health Investments, Corp. Updates Earnings Guidance for the Full Year 2024 CI
Clover Health Investments, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Clover Health Investments, Corp. authorizes a Buyback Plan. CI
Clover Health Investments, Corp. Announces Management Changes CI
Clover Health Investments, Corp. Announces CFO Changes CI
Clover Health Launches New Clinical Program in Partnership with quarter Health to Address Serious Mental Illness CI
Clover Health Investments, Corp.(NasdaqGS:CLOV) dropped from S&P Health Care Services Select Industry Index CI
Transcript : Clover Health Investments, Corp., Q4 2023 Earnings Call, Mar 12, 2024
Earnings Flash (CLOV) CLOVER HEALTH INVESTMENTS Reports Q4 Revenue $510.3M, vs. Street Est of $474M MT
Clover Health Investments, Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Clover Health Investments, Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Clover Health Investments, Corp. Reports Impairment of Goodwill and Other Intangible Assets for the Fourth Quarter Ended December 31, 2023 CI
More news
1 day+1.09%
1 week+12.36%
Current month+58.73%
1 month+53.85%
3 months+10.77%
6 months-3.85%
Current year+5.03%
More quotes
1 week
0.86
Extreme 0.8638
1.02
1 month
0.63
Extreme 0.6251
1.14
Current year
0.61
Extreme 0.606
1.14
1 year
0.61
Extreme 0.606
1.63
3 years
0.61
Extreme 0.606
28.85
5 years
0.61
Extreme 0.606
28.85
10 years
0.61
Extreme 0.606
28.85
More quotes
Managers TitleAgeSince
Founder 45 17/14/17
Founder 46 17/14/17
Director of Finance/CFO 52 29/04
Members of the board TitleAgeSince
Director/Board Member 68 07/21/07
Founder 46 17/14/17
Director/Board Member 44 01/17/01
More insiders
Date Price Change Volume
24/24/24 1 +1.09% 5,757,042
23/24/23 0.9892 -3.02% 5,789,938
22/24/22 1.02 +10.01% 8,178,859
21/24/21 0.9272 +3.54% 7,587,187
20/24/20 0.8955 +0.62% 4,866,913

Delayed Quote Nasdaq, May 25, 2024 at 01:30 am IST

More quotes
Clover Health Investments, Corp. is a physician enablement company. The Company is focused on seniors who have historically lacked access to affordable healthcare. It offers a software platform, Clover Assistant, which is designed to aggregate patient data from across the health ecosystem to support clinical decision-making and improve health outcomes. The Company operates under two segments: Insurance and Non-Insurance. Through its Insurance segment, it provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states. The Company's Non-Insurance segment consists of operations in connection with its participation in the Direct Contracting program. The Company’s subsidiaries include Clover Health Labs, LLC, Medical Service Professionals of NJ LLC, Clover HMO of New Jersey Inc., Clover Health Holdings, Inc. and Clover Health Partners, LLC.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1 USD
Average target price
1.333 USD
Spread / Average Target
+33.33%
Consensus